121 related articles for article (PubMed ID: 37474005)
1. The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer.
Makhlouf S; Althobiti M; Toss M; Muftah AA; Mongan NP; Lee AHS; Green AR; Rakha EA
Mod Pathol; 2023 Oct; 36(10):100284. PubMed ID: 37474005
[TBL] [Abstract][Full Text] [Related]
2. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
3. Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.
Dixon JM; Cameron DA; Arthur LM; Axelrod DM; Renshaw L; Thomas JS; Turnbull A; Young O; Loman CA; Jakubowski D; Baehner FL; Singh B
Adv Ther; 2019 Apr; 36(4):828-841. PubMed ID: 30859501
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
Iwamoto T; Booser D; Valero V; Murray JL; Koenig K; Esteva FJ; Ueno NT; Zhang J; Shi W; Qi Y; Matsuoka J; Yang EJ; Hortobagyi GN; Hatzis C; Symmans WF; Pusztai L
J Clin Oncol; 2012 Mar; 30(7):729-34. PubMed ID: 22291085
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives.
Malainou CP; Stachika N; Damianou AK; Anastopoulos A; Ploumaki I; Triantafyllou E; Drougkas K; Gomatou G; Kotteas E
Curr Oncol; 2023 Nov; 30(11):9734-9745. PubMed ID: 37999126
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
7. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
8. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract][Full Text] [Related]
9. Further evidence to support bimodality of oestrogen receptor expression in breast cancer.
Muftah AA; Aleskandarany M; Sonbul SN; Nolan CC; Diez Rodriguez M; Caldas C; Ellis IO; Green AR; Rakha EA
Histopathology; 2017 Feb; 70(3):456-465. PubMed ID: 27648723
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
11. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
14. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
15. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer.
Reinert T; Cascelli F; de Resende CAA; Gonçalves AC; Godo VSP; Barrios CH
Front Endocrinol (Lausanne); 2022; 13():1015388. PubMed ID: 36506043
[TBL] [Abstract][Full Text] [Related]
16. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
Chapman JA; Nielsen TO; Ellis MJ; Bernard P; Chia S; Gelmon KA; Pritchard KI; Le Maitre A; Goss PE; Leung S; Shepherd LE; Bramwell VH
Breast Cancer Res; 2013; 15(4):R71. PubMed ID: 23972025
[TBL] [Abstract][Full Text] [Related]
17. Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
Janeva S; Parris TZ; Nasic S; De Lara S; Larsson K; Audisio RA; Olofsson Bagge R; Kovács A
BMC Cancer; 2021 Apr; 21(1):439. PubMed ID: 33879115
[TBL] [Abstract][Full Text] [Related]
18. A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes.
Bari S; Boulware D; Li J; Loftus L; Soyano Muller A; Jameel Z; Khong H; Czerniecki BJ; Costa RLB
Breast Cancer (Dove Med Press); 2022; 14():199-210. PubMed ID: 35967746
[TBL] [Abstract][Full Text] [Related]
19. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
20.
Ichikawa T; Shibata M; Inaishi T; Soeda I; Kanda M; Hayashi M; Takano Y; Takeuchi D; Tsunoda N; Kodera Y; Kikumori T
Curr Oncol; 2021 Oct; 28(5):4080-4092. PubMed ID: 34677264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]